Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Work In Process (2022 - 2025)

Historic Work In Process for Gyre Therapeutics (GYRE) over the last 4 years, with Q3 2025 value amounting to $4.4 million.

  • Gyre Therapeutics' Work In Process rose 2536.05% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 2536.05%. This contributed to the annual value of $2.9 million for FY2024, which is 4667.0% up from last year.
  • Gyre Therapeutics' Work In Process amounted to $4.4 million in Q3 2025, which was up 2536.05% from $4.2 million recorded in Q2 2025.
  • Gyre Therapeutics' Work In Process' 5-year high stood at $4.4 million during Q3 2025, with a 5-year trough of $2.0 million in Q4 2023.
  • Its 4-year average for Work In Process is $3.3 million, with a median of $3.4 million in 2025.
  • Its Work In Process has fluctuated over the past 5 years, first plummeted by 4554.13% in 2023, then skyrocketed by 4667.0% in 2024.
  • Gyre Therapeutics' Work In Process (Quarter) stood at $3.7 million in 2022, then plummeted by 45.54% to $2.0 million in 2023, then surged by 46.67% to $2.9 million in 2024, then skyrocketed by 51.38% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.2 million for Q2 2025, and $3.4 million during Q1 2025.